
|Videos|August 29, 2017
Dr. Housri Discusses theMednet
Author(s)Nadine Housri, MD
Nadine Housri, MD, assistant clinical professor, Yale School of Medicine, discusses theMednet.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
AMH Testing Predicts Chemotherapy Benefit in RxPONDER Breast Cancer
3
How the Immune System Drives Nerve Growth in TNBC
4
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
5


































